Literature DB >> 2510985

Antimicrobial therapy. Cost-benefit considerations.

B J Guglielmo1, G F Brooks.   

Abstract

Mesh：

Substances：

Year:  1989        PMID： 2510985     DOI： 10.2165/00003495-198938040-00001

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  49 in total

1.  Intravenous followed by oral antimicrobial therapy for staphylococcal endocarditis.

Authors:  R H Parker; B E Fossieck
Journal:  Ann Intern Med       Date:  1980-12       Impact factor: 25.391

2.  Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions.

Authors:  J N Hayman; E C Sbravati
Journal:  Am J Hosp Pharm       Date:  1985-06

3.  Further observations on the value of oral penicillins in chronic staphylococcal osteomyelitis.

Authors:  S M Bell
Journal:  Med J Aust       Date:  1976-10-16       Impact factor: 7.738

4.  Effect of aminoglycoside-use restrictions on drug cost.

Authors:  O H DeTorres; R E White
Journal:  Am J Hosp Pharm       Date:  1984-06

5.  Effect of formulary restriction of cefotaxime usage.

Authors:  J M DeVito; J F John
Journal:  Arch Intern Med       Date:  1985-06

6.  Prospective cost analysis of moxalactam versus clindamycin plus gentamicin for endomyometritis after cesarean section.

Authors:  L C Knodel; B R Goldspiel; R S Gibbs
Journal:  Antimicrob Agents Chemother       Date:  1988-06       Impact factor: 5.191

7.  Metronidazole therapy of anaerobic bacteremia, meningitis, and brain abscess.

Authors:  J F Warner; R L Perkins; L Cordero
Journal:  Arch Intern Med       Date:  1979-02

8.  Cost containment through restriction of cephalosporins.

Authors:  H L Britton; T L Schwinghammer; M J Romano
Journal:  Am J Hosp Pharm       Date:  1981-12

9.  Cost-containment of antimicrobial therapy.

Authors:  S L Barriere
Journal:  Drug Intell Clin Pharm       Date:  1985-04

10.  Oral antimicrobial therapy for adults with osteomyelitis or septic arthritis.

Authors:  J Black; T L Hunt; P J Godley; E Matthew
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226
View more
  12 in total

1.  Technique for calculation of the true costs of antibiotic therapy.

Authors:  J R Kerr; J G Barr; E T Smyth; J O'Hare
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

2.  Intravenous-to-oral conversion therapy for antimicrobials.

Authors:  J M Conly; S D Shafran
Journal:  Can J Infect Dis       Date:  1994-01

3.  Hidden costs of antibiotics.

Authors:  E T Smyth; J G Barr; G M Hogg
Journal:  Pharmacoeconomics       Date:  1996-07       Impact factor: 4.981

Review 4.  Imipenem/cilastatin: a pharmacoeconomic appraisal of its use in intra-abdominal infections.

Authors:  P Benfield; P Chrisp
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 5.  Use of aminoglycosides in elderly patients. Pharmacokinetic and clinical considerations.

Authors:  K Mörike; M Schwab; U Klotz
Journal:  Drugs Aging       Date:  1997-04       Impact factor: 3.923

6.  Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  R Davis; H M Bryson
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

Review 7.  Teicoplanin. A pharmacoeconomic evaluation of its use in the treatment of gram-positive infections.

Authors:  C M Spencer; H M Bryson
Journal:  Pharmacoeconomics       Date:  1995-04       Impact factor: 4.981

Review 8.  Practical strategies for the appropriate use of antimicrobials.

Authors:  B J Guglielmo
Journal:  Pharm World Sci       Date:  1995-07-28

9.  Computerised calculation of the true costs of antibiotic therapy.

Authors:  J R Kerr; J G Barr; E T Smyth
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-08       Impact factor: 3.267

10.  Application of the ATC/DDD methodology to monitor antibiotic drug use.

Authors:  S Natsch; Y A Hekster; R de Jong; E R Heerdink; R M Herings; J W van der Meer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-01       Impact factor: 3.267
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.